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Background: A prerequisite for a successful design and discovery of an antibacterial drug is 
the identification of essential targets as well as potent inhibitors that adversely affect the survival 
of bacteria. In order to understand how intracellular perturbations occur due to inhibition of 
essential metabolic pathways, we have built, through the use of ordinary differential equations, 
a mathematical model of 8 major Escherichia coli pathways.
Results: Individual in vitro enzyme kinetic parameters published in the literature were used to 
build the network of pathways in such a way that the flux distribution matched that reported from 
whole cells. Gene regulation at the transcription level as well as feedback regulation of enzyme 
activity was incorporated as reported in the literature. The unknown kinetic parameters were esti-
mated by trial and error through simulations by observing network stability. Metabolites, whose 
biosynthetic pathways were not represented in this platform, were provided at a fixed concentration. 
Unutilized products were maintained at a fixed concentration by removing excess quantities from 
the platform. This approach enabled us to achieve steady state levels of all the metabolites in the 
cell. The output of various simulations correlated well with those previously published.
Conclusion: Such a virtual platform can be exploited for target identification through assessment 
of their vulnerability, desirable mode of target enzyme inhibition, and metabolite profiling to 
ascribe mechanism of action following a specific target inhibition. Vulnerability of targets in 
the biosynthetic pathway of coenzyme A was evaluated using this platform. In addition, we 
also report the utility of this platform in understanding the impact of a physiologically relevant 
carbon source, glucose versus acetate, on metabolite profiles of bacterial pathogens.
Keywords: antibacterial drug, mathematical model, kinetic platform, metabolic dynamics, 
Escherichia coli
Background
One of the main problems faced by the current paradigm of drug discovery in the 
therapeutic area of infection is in identification of a valid drug target, followed by 
an understanding of the concentration dynamics of the metabolites in response to its 
inhibition. A valid target at the genetic level is the one that is essential for the survival 
of the pathogen. At the functional level, the target protein structure and/or its biological 
activity is substantially different from that of the host. However, not all targets with 
these criteria yield inhibitors that kill the pathogen specifically through the mechanism 
intended. This necessitates generating a large number of targets suitable for high 
throughput screening (HTS).1 A recent review of anti-infective HTS by Payne et al 
indicated that the success rate is abysmally low even with a large number of HTS 
campaigns.2 Hence there is an urgent need to strategize and modify guidelines that 
define an ideal anti-infective drug target.Advances and Applications in Bioinformatics and Chemistry 2010:3 submit your manuscript | www.dovepress.com
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Many potent inhibitors of essential enzymes have been 
reported to lack antibacterial activity.3 In most cases, efflux 
or lack of permeability across the bacterial cell wall has been 
suspected to be a principal factor responsible for this phenom-
enon. This explanation has remained mainly unsubstantiated 
since it is difficult to determine the exact cause. However a 
quantitative relationship between enzyme inhibition and its 
effect on the growth of the pathogen has been delineated. 
Eisenthal and Cornish-Bowden have postulated two basic 
mechanisms by which the enzyme inhibition leads to the ces-
sation of growth of an organism: “either the flux through an 
essential metabolic pathway can be decreased to a point where 
life is no longer possible or metabolite concentration can be 
increased to toxic levels”.4 Recent evidence also indicates 
that independent of the target inhibited, bacterial cell death 
ultimately occurs through a generalized mechanism involving 
modulation of multiple pathways that leads to generation of 
free radicals.5 Thus there is a need to interconnect inhibition 
of target enzyme in vitro and inside the cell. It is well known 
that inhibition or over expression of an enzyme in a metabolic 
pathway does not guarantee either a change in flux or a con-
comitant increase or decrease in the metabolite concentration. 
The activity of any enzyme inside the cell depends on its own 
substrate concentration and kinetic properties (eg, Km,Vmax) 
as well as those of other enzymes in that particular pathway. 
On the other hand, the degree of enzyme inhibition inside 
the cell is related to the mode of enzyme inhibition (MOI) 
as well as to the enzyme-inhibitor dissociation constant (Ki). 
Therefore, it is essential to consider a network of enzymes or 
pathways around a particular target enzyme so as to predict 
the effect of its inhibition on the overall cell metabolism. 
Since target gene knockouts mimic complete inhibition inside 
the cell, it may not be possible to achieve the same inhibition 
through compound-mediated inhibition. It is thus necessary 
to assess the effect of partial inhibition through regulated 
expression of a target gene.6 Since this involves extensive 
experimentation, a better alternative is to predict cell vul-
nerability in response to a specific target enzyme inhibition 
through in silico simulations. Vulnerability is defined as the 
extent of inhibition of a target required to have a negative 
impact on growth leading to cell death.7
Towards this objective, we have built an in silico dynamic 
network of 8 major pathways in Escherichia coli, including 
glycolysis, pentose phosphate pathway, and tricarboxylic 
acid (TCA) cycle along with glyoxylate shunt, fatty acid 
metabolism, and biosyntheses of branched chain amino acids, 
pantothenic acid, and coenzyme A (CoA) (Figure 1). These 
pathways were chosen based on their connection to central car-
bon metabolism and their potential for possessing drug targets, 
for example, isocitrate lyase or pantothenate kinase, in drug 
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Figure 1 Schematic representation of pathways modeled on this platform. Each pathway is represented by central reactions or metabolites, truncated such for simplistic 
representation.
Pathway abbreviations: PPP, pentose phosphate pathway; Fatty Acid Metabolism, pathway of synthesis and breakdown of fatty acids; Pantothenate and CoA Syn, pathway 
of pantothenate and coenzyme A synthesis; BCAA synthesis, branched chain amino acid synthesis pathway; TCA and Glyx, pathways of tricarboxylic acid cycle and glyoxylate 
shunt; Methyglyoxal, methyglyoxal pathway.
Metabolite abbreviations: D-G6P, D-glucose-6-phosphate; Ru5P, ribulose-5-phosphate; Rib5P, ribose-5-phosphate; Xy5P, xylose-5-phosphate; G3P, glyceraldehyde-3-
phosphate; DHAP, dihydroxyacetone phosphate; PEP, phosphoenolpyruvate; Pyr, pyruvate; A-CoA, acetyl-CoA; OAA, oxaloacetate; Mal, malate; Suc, succinate; Isoc, isocitrate; 
Glyx, glyoxylate; Cit, citrate; Thr, Threonine; IsoL, isoleucine; Leu, leucine; Val, valine; ACP, acyl carrier protein; CoA, coenzyme A; Cys, cysteine; b-Ala, beta-alanine.Advances and Applications in Bioinformatics and Chemistry 2010:3 submit your manuscript | www.dovepress.com
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discovery against pathogens like Mycobacterium tuberculosis. 
Published data on enzyme kinetics, pathway flux distribution, 
operon structure, and gene regulation were used to build this 
platform. The pathway dynamics were simulated by inter-
connecting ordinary differential equations describing kinetic 
behavior of each enzyme in the pathway. Such a kinetic model 
is thus a computational and mathematical framework, built by 
using intracellular enzyme as well as metabolite concentration 
and other kinetic parameters. This platform is expected to elicit 
responses to perturbations in a fashion similar to the way the 
natural system in question would. This type of modeling has 
been referred to as an “impossible” problem, primarily because 
of the dearth of parametric data required to give meaning to 
flux equations, and, secondly, the absence of a software that 
can simulate and give stable solutions to systems comprising 
thousands of ordinary differential equations (ODEs). The 
proprietary Cellworks (Cellworks Group, Inc., Saratoga, 
CA, USA) technology, iC-PHYS™, can be used to create and 
simulate such a platform. Cell growth could be simulated by 
providing glucose or acetate as a carbon source (C-source) 
along with essential metabolites (metabolites not synthesized 
on this platform) such as beta-alanine, threonine, and cysteine. 
Altogether, 189 genes and 449 biochemical reactions covering 
434 metabolites were modeled on this platform. The model was 
aligned (see Materials and Methods – Alignment of the plat-
form) with data reported in the literature and “frozen” so that 
the subsequent validation studies did not require any alteration 
in the model parameters or equations. Validation studies were 
carried out using published data for E. coli. Various enzymes 
were evaluated as potential drug targets and those that were 
either vulnerable or relatively immune to inhibition of a spe-
cific type were identified and some experimentally verified. 
Since there is a significant overlap in the metabolic pathways 
among various bacteria, we tested the predictive capability of 
the in silico platform by correlating model predictions with 
experiments carried out on Mycobacterium bovis BCG as a 
surrogate for M. tuberculosis.
Results
Glycolysis, TCA cycle,  
and glyoxylate shunt
From the glycolytic pathway, tpiA (triose phosphate iso-
merase) knockout was used for validation. This   knockout 
showed normal cell growth due to activation of the 
methylglyoxal pathway and the flux distribution (Table 1) 
indicated 18-fold higher flux of dihydroxyacetone phosphate 
(DHAP) to methylglyoxal. This was similar to the 
experimental values reported earlier.8
Table 1 Comparison of predicted flux distribution values for tpiA 
gene knockout (KO) mutant with reported experimental values 
obtained using glucose as sole source of carbon
Reactions Evolved 
(800 generations) 
experimental 
KO/normal (tpiA)
Predictive 
KO/normal 
(tpiA)
Glucose + phosphoenol 
pyruvate (PEP) → glucose- 
6-phosphate (G6P) + 
pyruvate (PYR)
0.825 0.828
G6P ↔ fructose- 
6-phosphate (F6P)
1.05 1.02
Glyceraldehyde-3-phosphate 
(G3P) → PEP
0.503 0.57
PYR → acetyl-CoA 
(AcCoA) + CO2
1.01 1.16
G6P → 6-phospho- 
D-gluconate (6PG)
0.875 0.97
6PG → (D-ribulose 5- 
phosphate) Ru5P + CO2
0.96 0.93
AcCoA + oxaloacetate 
(OAA) → citrate (CIT)
1.89 1.16
Dihydroxyacetone 
phosphate (DHAP) → 
methylglyoxylate (MGLX)
83/UD 17.65
MGLX → PYR 83/UD 17.65
PEP + CO2 → OAA 0.878 0.8
Abbreviation: UD, undetectable levels.
The ability of the platform to predict growth of E. coli 
on acetate as C-source was tested and the resulting flux 
data compared with the reported values.9–11 With equimolar 
quantities of acetate or glucose as sole source of carbon, it 
was found that the rate of biomass generation on acetate was 
2.8-fold lower (Figure 2), comparable to the experimental 
value of 2.18. As a retrospective study, fluxes for various 
reactions in glycolytic pathway and TCA cycle including 
glyoxylate shunt were corroborated with the published data 
after appropriate normalization (Table 2). The predicted 
flux through the pentose phosphate pathway on acetate as 
C-source was higher than reported values. This discrepancy 
could be due to activation of trehalose biosynthesis after the 
osmotic imbalance experienced by E. coli growing on acetate 
as C-source, thereby accounting for the excess flux through 
the pentose phosphate pathway.12–14
The glyoxylate shunt consists of 2 enzymes, isocitrate 
lyase (AceA) and malate synthase (AceB). Strains like E. coli 
MG1665 have two isozymes (AceB and GlcB for malate 
synthase), while E. coli O:157 Sakai strain has only one of 
these. Here, we have considered only one malate synthase 
isozyme, which is AceB. Reported Km values for isocitrate are Advances and Applications in Bioinformatics and Chemistry 2010:3 submit your manuscript | www.dovepress.com
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604 and 12 µM for isocitrate lyase and isocitrate dehydrogenase 
(Icd), respectively. On glucose as C-source, most of the carbon 
flux is reported to go through Icd due to its higher affinity 
for isocitrate and its low intracellular concentration (30 µM). 
When acetate is used as C-source, aceBAK operon is switched 
on which in turn leads to inactivation of Icd by AceK through 
phosphorylation, resulting in an increased flux of isocitrate 
through glyoxylate shunt.11 Therefore, virtual knockouts of 
aceA and aceB were tested on the platform for the effects on 
the flux of isocitrate through the TCA cycle and glyoxylate 
shunt using acetate or glucose as C-source. It was observed 
that the flux from isocitrate to alpha-ketoglutarate was 2-fold 
higher on glucose whereas the flux through glyoxylate shunt 
was 10-fold higher on acetate. The relative flux distribution 
on acetate versus glucose was similar to that reported in 
the literature (Table 3).10 As expected, the rate of biomass 
generation declined when the C-source was changed from 
glucose to acetate for wild type and complete inhibition of 
growth was observed in both the knockouts (Figure 3A, 3B).
Fatty acid biosynthetic pathway
In this pathway, genes fabI, fabD, fabG, fabA, fabZ, and fabB 
are reported to be essential for cell growth.15 The experi-
mental knockout of fabF resulted in insignificant reduction 
Table  2  Comparison  of  flux  distribution  values,  normalized 
with respect to predicted uptake of acetate (16.9 µmoles/sec), 
obtained using acetate as sole source of carbon
Reactions Experimental 
relative flux (%)
Platform  
relative flux (%)
PEP → G3P 12.25 10.64
G6P → 6PG 2.18 8.64
6PG → Ru5P + CO2 2.18 8.64
AcCoA + OAA → CIT 71.58 72.14
ICT → alpha-keto glutarate 
(2-KG) + CO2
48.81 44.92
Malate (MAL) ↔ OAA 87.15 98.11
PEP + CO2 ↔ OAA 11.95 17.14
MAL → PYR + CO2 4.96 4.05
Isocitrate (ICT) → glyoxylate 
+ succinate (SUC)
22.77 27.22
Glyoxylate + AcCoA → MAL 22.77 27.22
Abbreviation: See Table 1.
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Figure 3 Essentiality of the glyoxylate shunt during growth on acetate as carbon 
source. Growth profile of E. coli after aceA A) and aceB B) gene knockout (KO): 
Initially, wild type (WT) E. coli cell growth was modeled on glucose followed by 
acetate. In the second phase, growth of gene knockout mutant of E. coli was modeled 
under similar conditions. Growth profile under each condition was modeled for 
12,000 seconds. Although both aceA and aceB knockout mutants showed a similar 
growth rate on glucose as that of wild type, they did not grow on acetate.
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Figure 2 Growth profile of an E. coli cell on glucose and acetate as carbon source. 
E. coli cell growth was modeled after providing equimolar quantities of glucose or 
acetate as the sole source of carbon. Rate of cell growth was found to be 2.8-fold 
higher on glucose than on acetate.
Table 3 Predicted changes in tricarboxylic acid (TCA) cycle and 
glyoxylate shunt fluxes upon change in sole source of carbon from 
glucose to acetate were compared with the reported values9
TCA and glycoxylate  
shunt
Experimental 
result
Predictive 
result
Reaction Ratio Ratio
AcCoA + OAA → CIT 3.58 1.65
CIT → ICT 3.58 1.81
ICT → 2-KG + CO2 2.58 0.514
2-KG → SUC 3.125 0.606
SUC ↔ fumarate (FUM) 4.416 1.943
FUM ↔ MAL 4.416 1.723
MAL ↔ OAA 5.312 3.22
ICT → glyoxylate + SUC Many folda 10.8
Glyoxylate + AcCoA → MAL Many fold 10.8
Notes: Table shows ratio of the flux on acetate to the flux on glucose. aFluxes were 
not detectable on glucose.
Abbreviation: See Tables 1 and 2.Advances and Applications in Bioinformatics and Chemistry 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
101
In silico modeling of metabolic dynamics in E. coli
in growth rate whereas fabI knockout did not grow at all. 
FabI is responsible for the conversion of trans-2-enoyl-acyl 
carrier protein (ACP) to a 2,3,4-saturated-ACP wherein both 
NADH and NADPH can be the reducing agents for the reac-
tion. A knockout of fabI results in growth inhibition since no 
other enzyme exists to catalyze this particular reaction. The 
fabF gene is involved in the formation of the beta-ketoacyl 
ACP form in the initiation as well as the elongation steps 
in saturated fatty acid biosynthesis. The knockout of fabF 
results in the flux diversion into other reactions carried out by 
FabB. Flux distribution in wild type and fabF knockouts can 
be seen in Tables S4 and S5. This experimental observation 
could be simulated in this model using the respective virtual 
gene knockouts at a constant glucose source concentration of 
670 µM. Knockouts were performed after permitting initial 
growth. The fabI knockout did not show growth whereas fabF 
knockout exhibited normal growth (Figure 4) as expected.
CoA biosynthetic pathway
Steady state levels of the total CoA pool as well as CoA and 
acetyl CoA, using glucose and acetate as the sole C-source 
generated using this platform (Table S2), were in close 
agreement with the experimental values reported in the litera-
ture.16 Multiple scenarios such as effects of overexpression of 
coaA, reduction in levels of CoA, and effect of pantothenate 
analogs on cell growth were simulated in this platform. The 
moderate (2- to 3-fold) increase in CoA levels following 
overexpression of coaA, inhibition of cell growth observed 
only after 95% reduction in CoA levels, and growth inhibi-
tion exerted by N5-pantothenate analogs through depletion 
of normal CoA levels (data not shown) were similar to the 
experimental observations reported in literature.17,18
The vulnerability of three major targets in this pathway, 
CoaA, CoaD, and CoaE, was assessed by predicting the 
minimum level of target enzyme inhibition required for 
the cessation of cell growth. Activity was modulated using 
gene knockdown as well as through various MOI. A gradual 
reduction in CoA levels was observed following stepwise 
knockdown of coaA (Figure 5B). On the other hand, a 
steep decline was observed only after 99% of coaE was 
knocked down (Figure 6B). As a result, growth inhibition 
was observed only after 99% knockdown of coaA or coaD 
(Figures 5A and 6A). A similar growth pattern was observed 
for coaE knockdown (data not shown). A reduction in CoA 
levels following knockdown of CoaD/E activity could, in 
turn, alleviate the feedback inhibition on CoaA activity, 
thereby compensating for the overall flux until 99% activity 
of CoaD/E is affected. In addition, the flux of the CoA path-
way was solely dependent on CoaA levels (data not shown). 
Both these observations indicated that the CoaA-catalyzed 
reaction was the rate-limiting step in this pathway. In spite 
of being described as a rate-limiting enzyme, more than 95% 
reduction in CoaA activity was required for growth inhibi-
tion, as the steady state levels of CoA were in large excess 
(20-fold) of what is critical for cell survival.
Enzyme inhibitors obtained during high throughput 
screening against an enzyme target could be competitive or 
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uncompetitive or noncompetitive with its substrate. After 
predicting the extent of target enzyme inhibition required 
for growth inhibition, various modes of CoaA inhibition 
were simulated with the aim of ranking them in terms of [I]/
Ki required for growth inhibition. The following equations 
were used to model an external inhibitor:
Competitive inhibition where the Km for ATP (adenosine 
tri-phosphate) increases −
KmATP =   KATP *(1 + ([CoA]/KiCoA) + ([Acetyl-CoA]/
KiACoA) + (I/Kie))
Uncompetitive inhibition where the Km for ATP as well 
as the Vmax decrease –
KmATP =   (KATP *(1 + ([CoA]/KiCoA) + ([Acetyl-CoA]/ 
KiACoA) + (I/Kie)))/(1 + I/Kies) and
Vf_app = Vf/(1 + I/Kies)
Since Kie ... Kies in the case of uncompetitive 
inhibitors, I/Kie in the numerator tends to zero. Therefore 
the net effect of I/Kies is a decrease in KmATP in the pres-
ence of an uncompetitive inhibitor. For pure noncompetitive 
inhibition, the Km for ATP remains the same while the 
Vmax decreases. On the other hand, mixed noncompeti-
tive inhibition entails an increase in the Km for ATP and a 
decrease in the value for Vmax.
The inhibitor was assumed to bind free enzyme wherein 
feedback inhibitors such as CoA or acetyl CoA could 
displace it. Predicted values of flux indicated that a mixed 
or pure noncompetitive inhibitor would require a 20-fold 
lower [I]/Ki ratio than the competitive inhibitor (Fig-
ure 7). This result is in accordance with the   Cheng-Prusoff 
relationship between enzyme IC50 and Ki values. Such pre-
dictions could be valuable in optimizing CoaA inhibitors 
to achieve potent antibacterial activity. Growth inhibition 
in the presence of a mixed noncompetitive inhibitor was 
preceded by a steady decline in CoA levels and simultane-
ous accumulation of pantothenate. The time delay observed 
for growth inhibition corresponded to the time required 
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A steep reduction in CoA levels was observed only after 99% knockdown of coaD 
(A). Similarly, inhibition of growth was observed only after 99% knockdown of coaE 
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for CoA levels to drop below a critical level of 5%. This 
could in turn imply that the cells might require an exposure 
to CoaA inhibitors for more than five generations for an 
effective growth inhibition.
Pantothenate biosynthetic pathway  
and its influence on CoaA activity
Valine and L-aspartate are the precursors for pantothenate 
synthesis in bacteria wherein the gene product of panC 
catalyzes the conversion of beta-alanine to pantothenate. 
The panCD knockout strain of M. bovis BCG was reported 
to grow in vitro with pantothenate supplementation and its 
growth rate was proportional to a pantothenate concentration 
of up to 10 µg/mL or 42 uM.19 Similarly, a virtual phenotype 
for panC knockout mutant could be demonstrated in this 
model wherein both steady state CoA levels and growth 
rate were proportional to a pantothenate concentration of 
up to 1 µM (Figure 8A and B). The lower concentration 
of pantothenate required to sustain normal growth on this 
platform could be due to the fact that 1 µM is simulated 
under intracellular milieu whereas 42 µM is present in the 
experimental growth medium.
Since poor growth of panC knockout under suboptimal 
pantothenate levels (,1 µM) was due to limiting levels of 
CoA, we wanted to test if the cell becomes more vulnerable to 
CoaA inhibition under this condition. As predicted, the extent 
of enzyme inhibition required for growth arrest declined 
from 99% under normal conditions for a wild type strain to 
70% for panC knockout (Figure 8C). It can be postulated 
that due to increased susceptibility to CoaA inhibition, the 
pantothenate auxotroph could be used for screening CoaA 
enzyme inhibitors for their antibacterial activity.
Branched chain amino acid biosynthesis
The acetohydroxyacid synthase (AHAS) class of enzymes 
catalyzes the first reaction in the biosynthetic pathway of 
branched chain amino acids leucine, isoleucine, and valine. 
AHAS I and III isozymes catalyze conversion of 2 pyruvate 
molecules into alpha-acetolactate for valine and leucine 
biosynthesis and 2 alpha-ketobutarate molecules into alpha-
acetohydroxybutyrate for isoleucine biosynthesis. Either 
AHAS I or AHAS III can support growth of E. coli in minimal 
media containing glucose as C-source whereas AHAS I alone 
has been shown to be essential when acetate is used as the sole 
source of carbon.20 On this platform, an auxotrophic pheno-
type was observed for the double knockout of AHAS I and III 
on glucose as well as acetate as C-source, wherein supplemen-
tation of all three amino acids could relieve growth inhibition 
(Figure 9A). Though the levels of isoleucine and valine started 
declining immediately after knockout, leucine was found to 
accumulate for a short period of time (Figure 9B). This was 
due to higher flux of 2-oxoisovalerate to 2-isopropylmalate 
through LeuA at the branchpoint of pathway for valine bio-
synthesis. This was confirmed by simultaneous knockout of 
leuA along with AHAS I and III where leucine accumulation 
was not observed (Figure 9C).
To evaluate the utility of this platform in other bacterial 
species like mycobacteria, the effect of a known AHAS 
inhibitor, flazasulfuron, on intracellular levels of leucine, 
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Figure 8 Growth profile and CoA levels in case of panC knockout (KO) with 
pantothenate  supplementation  and  effect  of  coaA  knockdown  under  these 
conditions. Effect of pantothenate supplementation (0.5, 1, 2, 4, 8 uM) on growth 
profile of panC knockout mutant of E. coli (A), CoA levels (B), and on growth 
profile of double mutant with panC knockout and coaA knockdown (percentage 
values indicate percentage knockdown.) (C). panC knockout results in pantothenate 
auxotrophy where normal growth was restored at 1 µM pantothenate (A). Steady 
state CoA levels in panC knockout mutant increased in proportion to the amount 
of pantothenate supplied (B). In a wild type strain, growth inhibition was observed 
only after 99% knockdown of coaA whereas in the case of panC knockout grown in 
the presence of 1 uM pantothenate, 70% knockdown of coaA was sufficient to cause 
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isoleucine, and valine in M. bovis BCG, a surrogate for 
M. tuberculosis, was experimentally validated. Following 
exposure to flazasulfuron, there was a reduction in the levels 
of leucine, isoleucine, and valine compared with untreated 
control (Table 4). This observation thus confirmed and experi-
mentally validated the predictions of the platform.
Discussion
Apart from the basic understanding of how the “tide and ebb” 
of metabolite flow is related to growth and death of bacteria, 
one of the major thrusts for carrying out dynamic modeling 
is to identify vulnerable drug targets. Though genome scale 
metabolic reconstruction has been attempted in silico for 
various organisms and more extensively so for E. coli,21,22 
it is difficult to incorporate enzyme kinetic parameters into 
these networks as many of these values are not known and 
the computational stability of such an operation is yet to be 
evaluated. On the other hand, individual pathways like the 
TCA cycle and the glyoxylate shunt have been simulated 
using in vitro kinetic parameters and used to derive valid cor-
relation between target inhibition and intracellular metabolite 
concentration.23 We have attempted simulating a network of 
eight major pathways including the central carbon metabo-
lism so that the effect of C-source on target vulnerability 
could be assessed.
Vulnerability can vary a lot depending upon the extent of 
cellular damage caused by the inhibition of a particular target. 
For example, only partial inhibition of DNA gyrase activity 
by fluoroquinolones results in cell death through induction of 
reactive oxygen species.5,24 In contrast, even 97% inhibition of 
the essential enzyme encoded by pyrG does not inhibit growth 
in Lactoccus lactis.25 In order to evaluate the vulnerability of a 
target, one would have to gradually reduce the level of target 
gene expression and simultaneously monitor the concomitant 
effect on bacterial growth. The method described here is 
well suited to predict and generate this critical information. 
Enzymes in the CoA biosynthetic pathway were evaluated 
for vulnerability using this platform. Predicted requirement 
of .95% enzyme inhibition sustained over 4 to 5 generations 
may pose a challenge in translating enzyme IC50s against 
CoaA, CoaD, and CoaE enzymes into MICs, especially 
against slow-growing bacteria like M. tuberculosis.
As the extent of inhibition depends on the nature of 
inhibition (competitive, uncompetitive, mixed), the current 
technology can also be exploited to choose the most effective 
class of inhibitors and, to a certain extent, reduce the chances 
of failure in translating nanomolar enzyme potencies into 
MICs. It has long been understood that some competitive 
inhibitors fail to inhibit the target enzyme within the cellular 
mileu due to substrate build up – a phenomenon described 
as metabolic resistance.26 The present technology would be 
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Figure 9 Effect of AHAS I, AHAS III knockout (KO) on growth and amino acid 
levels.  Growth  profile  (A)  of  AHAS  III  knockout  followed  by  AHAS  I  and  III 
double knockout with and without isoleucine 30 µM, leucine 135 µM, and valine   
200 µM (ILV) supplementation. Auxotrophic growth inhibition observed in the case 
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Table 4 Experimental validation of acetolactate synthase – inhibition
Amino acid Relative peak area – fold reduction
Extract  
(untreated)
Extract (flazasulfuron 
treated)
Valine 1 6.2
Isoleucine 1 2.68
Leucine 1 2.62
Notes: Levels of valine, leucine, and isoleucine following HPLC-based analysis of 
extracts of M. bovis BCG exposed to 8 µg/mL flazasulfuron. HPLC conditions: For 
the chromatography a C18 column (LUNA) was used at a flow rate of 1.0 mL/minute 
and the gradient conditions were as follows:10%–53% B in 24 minutes, 53%–100% 
B in 5 minutes, and 100%–10% B in 5 minutes. The amino acids were monitored at 
254 nm. The composition of the 2 buffers was as follows: buffer A – 140 mM sodium 
acetate containing 0.5 ml/L triethylamine, pH adjusted to 6.35 with acetic acid; buffer 
B – 60% acetonitrile.Advances and Applications in Bioinformatics and Chemistry 2010:3 submit your manuscript | www.dovepress.com
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able to depict such events, a valuable addition that would 
aid medicinal chemists in designing good inhibitors. In this 
platform, preference for the mixed mode of CoaA inhibition 
to achieve MICs at a lower inhibitor concentration was 
clearly predicted.
The central carbon metabolism and most of the auxiliary 
pathways that feed in and out of the system are generally 
conserved across the bacterial kingdom. However the differ-
ences that arise are in the values of kinetic parameters or in 
the number of orthologs coding for the same enzyme across 
species. Thus to migrate from one organism to another we 
need to do a correction of the kinetic parameters and align 
the system with its specific isoforms. If the major isoform 
is conserved across bacterial species, this E. coli platform 
could even be applied to those as distant as M. tuberculosis. 
Cross-species applicability of this E. coli platform was tested 
by comparing predictions made on pathways like branched 
chain amino acid/pantothenate/CoA biosynthesis with the 
experimental data generated using a mycobacterial species. 
Genes coding for 3 isoforms of AHAS (I, II and III) have been 
reported in E. coli. The ilvB1 gene codes for the major AHAS 
I activity whereas ilvG coding for AHAS II is not expressed in 
E. coli K-12. On the other hand, the M.   tuberculosis genome 
contains 4 genes (ilvB1, B2, G and X) coding for large cata-
lytic subunit of AHAS, whereas only 1 gene (ilvN or ilvH) 
codes for the smaller regulatory subunit of AHAS I. Predicted 
depletion of leucine, isoleucine, and valine following the 
virtual knockout of AHAS I was experimentally proven in M. 
bovis BCG using flazasulfuron, a known inhibitor of AHAS 
enzyme. Similarly, simulations done with the panC knockout 
aligned well with the experimental data reported for M. bovis 
BCG. The results indicated that a hybrid platform could give 
a satisfactory prediction where the major kinetic parameters 
were retained from E. coli and only minor differences in 
isoforms were incorporated from mycobacteria.
Conclusions
A network of 8 major metabolic pathways in E. coli was suc-
cessfully modeled and used for assessing target vulnerability, 
desirable biochemical mode of enzyme inhibition to get 
antibacterial activity, and to predict metabolite profiles upon 
target inhibition as a marker for studying the mode of action. 
Assessment of vulnerability and desirable mode of enzyme 
inhibition was illustrated using CoA biosynthetic pathway 
whereas change in branched chain amino acid levels illustrated 
its application in finding suitable metabolite markers following 
target inhibition. The emphasis behind this approach has been to 
address target “equity” beyond “essentiality”, a parameter long 
considered critical for its inclusion as an optimal candidate for 
designing drugs. The added feature that makes this simulation 
platform unique is its flexibility to incorporate different kinetic 
parameters or metabolite concentrations likely to be present 
either due to presence of alternative isoforms in different 
microorganisms, varied physiological environments, or changes 
in the intracellular milieu following treatment with various 
types of inhibitors. Our current pursuit is to build a kinetic in 
silico platform for M. tuberculosis that will include pathways 
unique to this pathogen especially those involved in cell wall 
biosynthesis. In addition, simulations to identify vulnerable tar-
gets in other druggable pathways in M. tuberculosis including 
energy metabolism, replication, transcription, and transla-
tion will also be run. This will lead to the construction of an 
integrated network of all pathways with the annotated essential 
genes from mycobacteria in this platform. Another advantage 
offered by this hybrid platform is its utilization to predict across 
unrelated bacteria the consequences of inhibition by various 
agents, provided they share and retain closely related target 
enzyme isoforms. In such cases, the simulation can be directly 
extrapolated and this was shown, albeit qualitatively, when the 
predicted modulation of levels of branched chain amino acids 
in flazasulfuron-exposed E. coli could be verified experimen-
tally and their actual levels confirmed in the M. tuberculosis 
surrogate, M. bovis BCG. Studies reported here have also 
demonstrated the feasibility of measuring the vulnerability of 
a few genes in E. coli. A follow-up re-evaluation of the same 
targets in mycobacteria by simulating a stepwise gradient of 
knockdown analysis will be an interesting study to pursue. 
Since mycobacterium switches its carbon utilization from C6 to 
C2 C-source while transiting from extracellular to intracellular 
mode of survival, a major highlight of this model would be its 
capability to simulate this biological plasticity. The creation of 
a kinetic model of the size and complexity described here is 
a new advancement in the field of systems biology. We invite 
questions, which can be verified by experimental observations 
thereby shifting this conceptually “impossible” problem into 
the realm of experimental possibility. In short, this will be a 
visualization tool that will predict target vulnerability and its 
impact on cellular viability, consequent on blockage of impor-
tant pathways either through genetic or chemical means tested 
under varied conditions.
Materials and methods
Model construction
Eight pathways in E. coli including glycolysis, pentose 
phosphate shunt, TCA cycle, fatty-acid metabolism, 
branched-chain amino acid synthesis, and CoA synthesis were Advances and Applications in Bioinformatics and Chemistry 2010:3 submit your manuscript | www.dovepress.com
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modeled on this platform (Figure 1). These pathways were 
integrated with each other and the end products were assimi-
lated into macromolecules such as DNA, RNA, proteins, and 
lipids, as per the known stoichiometry.27 E. coli growth, rep-
resented as a combined mass of macromolecules mentioned 
above, was simulated on glucose (C6) or acetate (C2) as 
C-source under aerobic growth conditions. A typical simula-
tion starts with zero biomass and an increase in the same is 
indicative of cell growth. Gene regulation through various 
metabolites and regulatory proteins as per the C-source was 
included but the mechanism of regulation of over expression 
of regulatory proteins was not considered. The static map 
representation for each pathway and the operon information 
was adopted from the published literature.28 This platform was 
built as a dynamic model with each reaction represented by 
an ordinary differential equation so that it could predict the 
quantitative effects of perturbation in any pathway on all the 
reactions included on this platform. The key aspects of this 
model are qualitatively described in this section, with impor-
tant equations and mechanisms tabulated in Table S3.
Central carbon metabolism was modeled using glycoly-
sis coupled to TCA cycle along with the glyoxylate shunt to 
accommodate acetate as an alternative C-source. Important 
regulatory mechanisms such as regulation of enzyme activity 
of phosphofructokinase (PfkA, PfkB) by ATP, regulation of 
isocitrate lyase (aceA) gene expression and enzymatic activity 
by pyruvate, glyoxylate, and succinate were taken into account. 
Pentose phosphate pathway and the Entner–Duodoroff path-
way were modeled for generating pentose sugars as nucleic 
acid precursors and glycolytic intermediates, respectively. 
Metabolites such as ribose 5-phosphate and pyruvate were 
used for the biosynthesis of nucleotides and peptidoglycan/
protein respectively. Fatty acid metabolism was modeled 
to supply C14, C16, and C18 derivatives for the synthesis 
of membrane lipids. Feedback inhibition of acetyl-CoA 
carboxylases (AccABCD) and beta-ketoacyl-ACP synthase 
(FabH) through fatty-acyl-ACPs was built into the regulation 
of fatty acid synthesis.29,30 Synthesis of branched chain amino 
acids (BCAA) such as leucine, isoleucine, and valine was 
regulated by stringent feedback inhibition and using   different 
isoforms.31 Out of 3 isoforms of acetohydroxybutanoate 
  synthase (AHAS I, AHAS II, AHAS III), AHAS II flux 
was not considered as it was reported to be nonfunctional 
in E. coli.32 CoA biosynthesis was linked to BCAA synthesis 
through 2-  ketoisovalerate which was used as a precursor of 
pantothenate. Pantothenate was converted to CoA through 
a series of 4 reactions catalyzed by gene products of coaA, 
coaB/C, coaD, and coaE. CoA was utilized as a major cofactor, 
an acyl group donor during protein and fatty acid biosynthesis. 
In addition, feedback regulation of CoaA and CoaD by CoA 
was incorporated. Considering the limits of this platform, 
some of the precursors, which were not synthesized on this 
platform, were supplied externally at the required stoichiom-
etry. Metabolites produced in this model as well those supplied 
externally were incorporated into macromolecules required for 
the cell growth and the excess products were removed to avoid 
their undesirable effects on the modeled enzyme activities.
Model assumptions
Beyer et al in their studies on yeast, reported strong correla-
tion between mRNA and protein levels in modules such as 
“energy”, “metabolism”, hinting at the possibility of strongly 
synchronized regulation of expression within functionally 
homogenous modules.33 Similarly, correlation between overall 
mRNA and protein abundance in E. coli using codon adap-
tation index as a measure of gene expressivity was reported 
earlier.34 Therefore relative enzyme concentrations on this 
platform were normalized using mRNA profiles reported 
under various growth conditions of E. coli. The platform was 
built to model growth of E. coli using glucose or acetate as 
C-source. Nitrogen source, oxygen, and other nutrients such as 
metal ions were externally provided in abundance. In reactions 
where one of the substrates was not produced on the platform, 
for example, b-alanine in the reaction catalyzed by pantoate 
b-alanine ligase, it was provided externally at the concen-
tration reported.35 Generation of ATP using   proton motive 
force was not considered but the generation of ATP through 
reducing equivalents was incorporated. Total concentration 
of ATP, ADP (adenosine diphosphate), and AMP (adenosine 
monophosphate) pool was kept constant by incorporating 
interconversion of these forms through adenylate kinase-
catalyzed reaction. The stoichiometry of ATP produced during 
electron transport through NDH-1, NDH-2, and cytochrome 
‘bo’ was incorporated assuming a constant high energetic 
efficiency.36 While interpreting flux distribution under   various 
test conditions, the relative values of flux or metabolite con-
centration were compared with reported values. As data for 
in vitro enzyme assays may not always correlate with in vivo 
conditions, the simulation time had no relation to the actual 
time required for cell growth.
Model alignment and validation
The Cellworks proprietary technology, iC-PHYS™, has the 
ability to solve systems comprising an unlimited number Advances and Applications in Bioinformatics and Chemistry 2010:3 submit your manuscript | www.dovepress.com
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of simultaneous ODEs.37 It has been tested for systems 
of about 4000 ODEs. The integrity of the iC-PHYS™ was 
corroborated by comparing its performance with analytical 
solutions obtained at various time points in a concentration 
decay experiment. Further, comparison was carried out 
between the performance of iC-PHYS™ and Cell Designer 
4.0.138,39 for time-dependent change in the concentration of 
2 species within the MAPK system,40 an oscillatory signaling 
cascade. The correlation observed between iC-PHYS™ and 
Cell Designer 4.0.1 was found to be 0.98.
The iC-PHYS™ engine represents a reaction in a given 
pathway as a kinetic equation capturing the mechanistic 
data of an enzyme. Further inputs are in the form of kinetic 
parameters after which concentration of modeled species and 
other variables are linked through appropriate ODEs. Thus, 
iC-PHYS™ consists of a 3-tier architecture (Figure 10), a 
computational back plane at the foundation level which 
solves these differential equations, and outputs data in the 
form of reports and plots whereas the middle layer com-
prises a static pathway map linked to in vitro enzymatic 
data and in vivo fluxes. With these 2 layers together form-
ing a background platform, the user interface has a viewer 
layer where the growth profiles as a result of simulation 
can be visualized and analyzed. Change of the fluxes, and 
metabolite and enzyme concentration with time can also 
be monitored.
Creation of the platform started with the computational 
representation of a static map of the pathway to be modeled. 
In instances of inconsistent or unknown enzyme kinetic 
parameters, a trial and error method of optimization was 
followed to attain physiological enzyme behavior. The 
kinetic parameters (eg, rate constants [Kf or Kr], Km, Vmax 
[Vf]), concentrations of the substrates and products, reac-
tion equation showing the stoichiometry of substrates and 
products participating in the specific biochemical reaction, 
flux equation or kinetic equation for the individual reaction, 
and compartment (cytosol or membrane or pseudo) where 
the reaction takes place are provided in the supplementary 
PDF document (Model equations and parameters). All the 
448 reactions used in this platform are described in this 
document. After alignment, the kinetics of the reaction were 
frozen and validated against various experimental results 
in literature. All pathway modules were thus aligned for 
physiological effects and then validated against published 
information and/or live experimental data. A thorough 
qualification of standalone models with respect to bio-
logical accuracy ensured physiological behavior when 
Growth profiles
GUI: Graphical user interface
Static pathway map linked to
in vitro enzyme data
and in vivo fluxes
Mathematical Engine 
(Solver and plotter)
E.coli metabolic network
Figure  10  Schematic  representation  of  the  iC-PHYS™  engine  with  a  3-tier 
structure. The mathematical engine, comprising the solver and the plotter, forms 
the foundation of iC-PHYS™. The interconnected E. coli map with relevant kinetic 
parameters  and  equations  forms  the  secondary  layer,  while  the  graphical  user 
interface (GUI) forms the uppermost layer. The user manipulates and generates 
data by using the GUI.
assessed as closed systems. Individual pathway modules 
were then integrated wherein kinetic parameters were 
aligned wherever necessary by following the optimization 
method described above. Thus the complete platform was 
aligned with training data sets in the form of experimental 
results reported in the literature so as to ensure reliability 
in predicted values. The rate of glucose utilization and Advances and Applications in Bioinformatics and Chemistry 2010:3 submit your manuscript | www.dovepress.com
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the flux distribution on the platform were aligned to the 
experimentally reported values.34,41 The comparison of 
relative flux distribution in E. coli grown in a continuous 
culture mode with that simulated on the platform is given 
in Table S1.
The enzyme levels on the platform were aligned to the 
microarray profiles generated using E. coli MG1655 grown 
on a glucose-containing minimal medium.42 The microar-
ray data were extracted from the NCBI GEO database and 
normalized against the gene panE that was expressed at 
similar levels on glucose as well as acetate as a C-source. 
This method was adopted to reduce the intensities to a smaller 
magnitude, thereby reducing the ODE solver complexities 
associated with numbers of large magnitude.
Generic simulation procedure
All the simulations in this E. coli platform were done 
using the iC-PHYSTM graphical user interface (GUI). 
The iC-PHYSTM GUI grants the user the option to set the 
maximum biological time of the simulation, specify the 
C-source, and the mode (continuous or batch supply of 
C-source) for a particular experiment. Different virtual 
experiments could be conducted on this platform. For 
example, aceA knockout was tested for its effect on fluxes 
in the TCA cycle and the glyoxylate shunt. The simulation 
was carried out for a total time of 48,000 seconds under 
4 different conditions of 12,000 seconds each. The first 2 
conditions were set up to simulate the growth of wild type 
E. coli using a continuous supply of glucose (670 µM) fol-
lowed by acetate (2010 µM). The next 2 conditions were set 
up to simulate the growth of aceA knockout mutant under 
similar growth conditions to that of wild type. Similarly, 
the effect of a specific percentage knockdown or overex-
pression of a particular enzyme or enzymes on the growth 
of E. coli cell was simulated. For example, coaA, coaD, 
and coaE were knocked down by different percentages to 
assess the vulnerability of cell growth to inhibition of these 
targets. Concentration of a desired metabolite could be 
altered to study the effect of that metabolite on cell growth. 
For example, the auxotrophy phenotype for the AHAS I/III 
knockout was tested by supplementing leucine, isoleucine, 
and valine at fixed concentrations. In such simulations, the 
concentration of a metabolite generated by the platform 
under knockout or knockdown conditions was changed to 
a fixed value in the second stage of supplementation. This 
procedure could also be employed to check the effect of 
variation in enzyme kinetic parameters in the presence of 
external inhibitors. For example, effect of CoaA inhibitors 
with different [I]/Ki ratio and various MOI was simulated 
to examine their effect on cell growth.
Experimental validation  
of predictions made using  
this platform
Intracellular levels of branched chain amino acids were 
estimated after subjecting whole cells of M. bovis BCG to 
a suitable extraction procedure43 followed by detection and 
analysis by HPLC. Flazasulfuron, a reported AHAS inhibitor44 
with an MIC of 2 µg/mL against M. bovis BCG, was tested 
for its effect on intracellular levels of isoleucine, leucine, and 
valine. M. bovis BCG was grown in roller bottles in Middle 
Brook 7H9 (0.05% Tween and ADC) at 37°C until OD600 
reached 0.5. The bacterial cells were exposed to the inhibitor 
and re-incubated at 37°C for 4 hours. The treated cultures were 
harvested and washed with phosphate buffered saline. The 
cell pellets were resuspended in chilled 0.6 M perchloric acid, 
vigorously mixed, and left on ice for 30 minutes. These acid 
extracts were neutralized using 0.6 M KOH, recentrifuged, 
and the supernatant vacuum was dried and then reconstituted 
in water for derivatization45 prior to HPLC analysis. These 
extracts were resuspended in derivatization buffer containing 
50 µL of PITC (phenylisothiocyanate), 350 µL ethanol, 50 µL 
triethylamine, and 50 µL water, incubated for 30 minutes at 
25°C, and dried in vacuum again. All samples were resus-
pended in buffer A (140 mM sodium acetate containing 
0.5 mL triethylamine/L, pH adjusted to 6.35 with acetic acid) 
containing 10% acetonitrile prior to injection into HPLC 
column (C18 LUNA). Gradient used was buffer A to B (60% 
acetonitrile): 10% to 53% B in 24 minutes, 53% to 100% B in 
5 minutes,100% to 10% B in 5 minutes, and the finally back 
to 10% B in 5 minutes at a flow rate of 1 mL/min. Derivatized 
amino acids were monitored for absorbance at 254 nm.
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